Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

74

CHICAGO–(BUSINESS WIRE)–Xeris announced positive findings from a global Phase 3 trial of its ready-to-use (RTU) room-temperature stable liquid glucagon conducted in Europe….

 

 

 

 

 

 

 

http://www.businesswire.com/news/home/20190617005256/en/Xeris-Pharmaceuticals-Announces-Additional-Positive-Outcomes-Global/